Introduction
Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta (Wooten 1997) . PD affects approximately 1 % of people older than 65 years of age. Principle symptoms associated with PD are rigidity, bradykinesia, resting tremor, and postural instability along with cognitive and psychiatric complications (Paulus and Jellinger 1991; Sherer et al. 2001) . Currently, the most effective therapy for PD involves restoration of the dopaminergic neurotransmission by administration of levodopa (Birkmayer and Hornykiewicz 2001; Cotzias et al. 1969) , the precursor of dopamine (Lopez et al. 2001) . However, as the disease progresses, the levodopa therapy often results in the emergence of motor complications consisting of on-off phenomena and levodopa-induced dyskinesias (Marsden and Parkes 1976) . As an alternative to levodopa, dopamine receptor agonists are also used clinically to treat PD (Clarke and Guttman 2002; Dutta 2006; Foley et al. 2004) .
Dopamine receptors are members of the G proteincoupled receptor (GPCR) family of proteins. They are classified into two main subfamilies based on their sequence homology and pharmacological properties. The D 1 -like dopamine receptors include D 1 and D 5 receptor subtypes, whereas the D 2 -like dopamine receptors include D 2 , D 3 , and D 4 receptor subtypes (Civelli et al. 1993; Giros et al. 1990 ; Kebabian and Calne 1979; Sokoloff et al. 1990; Strange 1993; Sunahara et al. 1991; Van Tol et al. 1991) .
The stimulation of D 1 -like receptors leads to activation of adenylate cyclase, which promotes synthesis of cAMP, whereas D 2 -like receptor activation leads to inhibition of adenylate cyclase activity. In the CNS (central nervous system), D 1 -like receptors are located postsynaptically, whereas D 2 -like receptors are located both pre-and postsynaptically and have high affinity for dopamine (Emilien et al. 1999) . In addition to adenylate cyclase, the D 2 -like dopamine receptors also couple to several signaling pathways, including the mitogenactivated protein kinase (MAPK) pathway and G proteincoupled inward rectifier potassium (GIRK) channels. In vitro and in vivo studies have also shown that D 2 -like receptors modulate cell proliferation (Winner et al. 2009 ).
Currently, a number of dopamine receptor agonists are being used in the clinic to treat PD. Some of these agonists are ergot alkaloids and include pergolide, bromocriptine, and lisuride. Recently, newer, nonergot classes of molecules, pramipexole and ropinirole, along with apomorphine have been clinically used (Rascol et al. 1998; Rinne et al. 1998) . Most dopamine receptor agonists with antiparkinsonian effects have high affinity for D 2 and D 3 receptors. Interestingly, two dopamine receptor agonists that are used clinically, ropinirole and pramipexole, have a higher affinity for D 3 receptor compared to D 2 receptor. Results from in vitro and in vivo studies have indicated that D 3 receptor activation can potentially afford neuroprotection (Du et al. 2005; Joyce 2001) .
Recently, we reported the development of novel D 3 -preferring agonists based on our hybrid template. One of our lead compounds, (−)-N 6 -(2-(4-(Biphenyl-4-yl)piperazin-1-yl)ethyl) -N 6 -propyl-4,5,6,7-tetrahydrobenzo[d] thiazole-2,6-diamine (D-264) exhibited high affinity and good selectivity for the D 3 receptor (Biswas et al. 2008a; Biswas et al. 2008b; Johnson et al. 2012) (Table 1 ). This compound demonstrated potent antiparkinsonian activity in 6-OHDAlesioned animal models of PD (Biswas et al. 2008a) . Furthermore, in our in vivo neuroprotection study, using both acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and progressive lactacystin mouse models of PD, we demonstrated that D-264 significantly improved the behavioral symptoms of PD (Li et al. 2010) . D-264 exhibited pronounced neuroprotective effect in both the MPTP-and lactacystin-lesioned models as the animals pretreated with D-264 maintained a significant number of tyrosine hydroxylase-positive cells and had normal levels of dopamine and its metabolites (Li et al. 2010 ). The neuroprotective effect of D-264 was specifically mediated by D 3 receptors as pretreatment with D 3 receptor-preferring antagonist ,U99194, blocked the D-264-induced neuroprotection (Li et al. 2010) . While implicating D 3 receptors, these in vivo studies with D-264 did not determine if the neuroprotection was mediated directly by D 3 receptor signaling pathways or indirectly through production of trophic factors. In this paper, we directly evaluated the effect of D-264 on signaling mediated by D 2 and D 3 receptors heterologously expressed in AtT-20 neuroendocrine cells.
The D 3 receptor has been previously shown to couple to MAPK signaling and GIRK channels in AtT-20 neuroendocrine cells stably expressing human D 3 receptors (Kuzhikandathil et al. 2004; Westrich and Kuzhikandathil 2007 
Methods

Cell culture
AtT-20 mouse pituitary cells were grown in Ham's F10 medium with 5 % FBS (Fetal Bovine Serum), 10 % heatinactivated horse serum, 2 mM glutamine, and 50 μg/ml gentamicin (Invitrogen, Carlsbad, CA, USA). AtT-20 cells stably expressing the human D 2S , D 2L , and D 3 receptor were maintained in the above F10 culture media supplemented with 500 μg/mlG418 (Invitrogen). For electrophysiological characterization, cells were plated onto glass coverslips coated with 40 μg/ml poly-L-lysine (Sigma-Aldrich, St. Louis, MO, USA). The generation and characterization of the AtT-20 cells stably expressing various human dopamine receptors have been previously reported (Kuzhikandathil and Bartoszyk 2006; Kuzhikandathil and Oxford 1999) .
Electrophysiology
Agonist-activated GIRK currents were measured by the wholecell patch clamp technique in voltage clamp mode as described previously (Kuzhikandathil and Bartoszyk 2006; Kuzhikandathil and Oxford 1999; Kuzhikandathil et al. 1998) . Briefly, cells were held at −65 mV and inward K + currents induced by drug solutions were measured. The Standard external solution (SES) used for K + current measurements was: 145 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM hepes [pH7.4], and 10 mM glucose and the pipette solution contained: 130 mM Kaspartate, 20 mM NaCl, 1 mM MgCl 2 , 10 mM hepes [pH7.4], 10 mM glucose, 0.1 mM Guanosine 5'-triphosphate (GTP), 5 mM Mg-ATP (adenosine 5'-triphosphate), and 1 mM Ethylenebis (oxyethylenenitrilo) tetraacetic acid (EGTA). To enhance inwardly rectifying K + currents, controls and drug exposures were performed in solutions with elevated extracellular [K+] (30 mM) by substitution for Na + . (−) Quinpirole (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in water and used at indicated concentrations. A 10 mM stock of D-264 was freshly dissolved in dimethyl sulfoxide (DMSO), diluted in SES, and used at indicated concentrations. Drug solutions were delivered to cells via a multibarreled micropipette array. The current responses were normalized to the cell capacitance to account for variation in cell size.
Detection of ERK phosphorylation
For the MAPK studies, cell lines were grown in six-well plates until 80-90 % confluent. The cells were incubated in Opti-MEM serum-free medium (Invitrogen) for 3 h prior to treatment. The cells were then pretreated with either 100 nM D-264, 200 nM quinpirole, or SES for 1 min, followed by several thorough SES washes for 30 min. Both control and pretreated cells were thoroughly washed several times in SES for a total of 30 min. The wash procedure included three quick rinses with 3 ml of SES, followed by six rinses with 3 ml SES. Each of the six rinses was for 5 min at room temperature (25°C). Subsequently, the cells were treated with SES, 200 nM quinpirole, or 100 nM D-264 for 5 min and lysed using a lysis reagent (62.5 mM Tris-Cl [pH6.8], 10 mM sodium fluoride, 1 mM phenylmethylsulphonyl fluoride (PMSF), 1 mM sodium orthovanadate, 1 mM ethylenediaminetetraacetate (EDTA), 1 mM EGTA, 200 mM dithiothreitol (DTT), 1 μg/ml phosphatase inhibitor (Sigma-Aldrich), 1 μg/ml protease inhibitor cocktail (Sigma-Aldrich), 2 % sodium dodecyl sulfate (SDS), 0.5 % TritonX-100, and 10 % glycerol). Following centrifugal clarification, the supernatants were boiled for 3 min at 95°C and 30 μl of cell lysate was loaded on a 10 % SDS polyacrylamide gel. The separated proteins were electroblotted onto nitrocellulose membrane and blocked in 5 % nonfat milk. Activated (phosphorylated) MAPK were first detected using monoclonal phospho-p44/p42 MAPK antibody (1:1,000 dilution; Cell Signaling Technology, Danvers, MA, USA). Following the detection of phosphorylated proteins, the membrane was stripped and reprobed to detect total MAPK proteins. Total MAPK proteins were detected using a polyclonal antibody (1:1,000 dilution; Cell Signaling Technology) overnight at 4°C. Horseradish peroxidase conjugated anti-mouse or anti-rabbit secondary antibodies (1:2,000, Pierce Biochemicals, Rockford, IL, USA) and SuperSignal® West Dura extended duration substrate chemiluminescence detection kit (Pierce Biochemicals, Rockford, IL, USA) were used to detect the signals. Immunoblots shown are from representative experiments that were repeated at least three independent times with comparable results. (Figs. 2 and 3 ). In addition, as reported previously, (Westrich and Kuzhikandathil 2007) , the D 3 receptor exhibits tolerance wherein the cells pretreated with agonist elicits a significantly reduced second response (Fig. 3) Werner et al. 1996) . Figure 4 shows that D-264 activates endogenous GIRK channels in AtT-20 cells stably expressing human D 2S , D 2L , or D 3 dopamine receptors; no activation is observed in control parental AtT-20 cells (Fig. 4a) . In D 2S -and D 2L -expressing cells, the GIRK currents elicited by D-264 showed different kinetics of inactivation compared to GIRK currents elicited by quinpirole ( Fig. 4b-d (Fig. 4f) . D-264 dose-dependently activated GIRK currents in AtT-20 cells stably expressing human D 2S , D 2L , or D 3 dopamine receptors. The magnitude of normalized currents elicited by high concentration (300 nM) of D-264 was not significantly different from those elicited by high concentration (300 nM) of the full agonist quinpirole (Fig. 5) . (Hetman et al. 1999) . The activation of MAPK is involved in cell survival, growth, and differentiation (Xia et al. 1995) . Stress-induced activation of MAPK pathways has been shown to be a mechanism for neuroprotection in the CNS (Impey et al. 1998 The maximum effect on cell proliferation (121 %) compared to untreated control (100 %) was observed at 1 nM (Fig. 6a) . AtT-D 3 cells were treated with concentrations of D-264 that ranged from 10nM to 0.00001 nM and a dose-dependent effect was observed, with the maximum effect on proliferation (128 %) observed at 0.001 nM (Fig. 6b) . Comparing D 2 and D 3 receptors, it was found that the concentration of D-264 that induced the highest cell proliferation in D 3 receptor-expressing cells was 1,000-fold lower compared to D 2L receptor-expressing cells (Fig. 6a and b) . The reference agonist quinpirole induced the highest proliferation (147 %) of D 3 receptor-expressing AtT-20 cells at 0.0001 nM (Fig. 6c) . Interestingly, we also observed that high concentrations of D-264 did not induce proliferation of AtT-20 cells stably expressing the D 3 receptor but did induce proliferation of AtT-20 cells stably expressing the D 2L receptor (Fig. 6) . The levels of D-264-induced P-p44/p42 MAPK proteins were normalized to the levels of total p44/ p42 MAPK proteins. The experiments were repeated three independent times. *, #, Ψ, P<0.05, statistically significant, ANOVA, post hoc Holms test. *, comparing control (−/−) to samples that received 2nd treatment only (−/+). #, comparing control (−/−) to samples that were only pretreated (+/−). Ψ, comparing samples that received pretreatment only (+/−) to those that received both treatments (+/+)
Discussion
Our multifunctional drug development effort is directed toward developing antiparkinsonian drugs with neuroprotective properties. In this endeavor, we designed and synthesized a unique series of D 3 receptor-preferring molecules with hybrid molecular structure. In our previous study, one of our lead molecules, D-264, with potent agonist activity at both D 2 and D 3 receptors, was shown to be neuroprotective in two wellestablished animal models (Li et al. 2010) . The D-264-mediated neuroprotection is partly attributable to its interaction with the D 3 receptors (Li et al. 2010 ). The D 3 receptor has been previously implicated in neuroprotection as D 3 receptorpreferring agonists, such as pramipexole and ropinirole, protected dopamine (DA) neurons against MPTP and 6-hydroxydopamine (6-OHDA) neurotoxicity more robustly than less selective D 3 receptor-preferring agonists (Iida et al. 1999; Ramirez et al. 2003) . It has been suggested that the neuroprotective role of D 3 receptor is mediated indirectly via production of trophic factors such as brain-derived neurotrophic factor (BDNF) and glial cell line-derived factor (GDNF). Indeed, D 3 receptor stimulation induces expression of BDNF as demonstrated in studies wherein D 3 receptor-preferring agonists induced production of neurotrophic factors such as BDNF and GDNF in cultured mesencephalic DA neurons and also in differentiated SH-SY5Y cells (Du et al. 2005; Joyce and Millan 2007) . An alternate hypothesis is that the neuroprotective effect of D 3 receptor is directly mediated by its robust activation of MAPK signaling and GIRK channels. Both signaling effectors have been previously shown to were determined by comparing to control (vehicle) which was set to 100%. *, P<0.001, ANOVA, Tukey's multiple comparison test showed statistically significant difference between control and some treatments (n=3 to 4) mediate cell proliferation (Xia et al. 1995; Plummer et al. 2005) . MAPK signaling plays an important role in different neuronal functions (Hetman et al. 1999 ) and the activation of MAPK has been shown to contribute to cell survival, growth, and differentiation (Xia et al. 1995) . Stress-induced activation of MAPK pathways has been shown to be one of the mechanisms for neuroprotection in the CNS (Impey et al. 1998) . Studies in cancer cell lines have shown that specific inhibition of GIRK channels suppresses cancer cell proliferation (Plummer et al. 2005 ). This would suggest that activation of GIRK channels by D 2 -like dopamine receptors might also promote cell proliferation. The objective of our current study was to evaluate the effect of novel D 2 /D 3 receptor agonist, D-264, on MAPK and GIRK channel activation and determine its ability to modulate cell proliferation. Our results show that D-264 potently activated the MAPK signaling pathway coupled to D 2S , D 2L , and D 3 receptors (Figs. 1, 2, 3) . D-264 also robustly induced GIRK current in AtT-20 cells stably expressing D 2S , D 2L , and D 3 receptors as evidenced in Fig. 4b-d . D-264 was equally efficacious at activating GIRK channels coupled to D 2 or D 3 receptors (Fig. 5) ; this observation, when taken in the context of the data in Table 1 , suggests that D-264 might exhibit functional selectivity wherein it exhibits selectivity in some signal transduction pathways (MAPK, cell proliferation) but not others (GIRK).
While both D-264 and quinpirole activated MAPK signaling and GIRK channels, they differed in duration of activation. Unlike quinpirole, D-264-mediated activation of D 2 /D 3 receptor signaling exhibited persistent activation (Figs. 2, 3, 4) . D-264-induced MAPK and GIRK channel activation persisted in AtT-20 cells stably expressing D 2S , D 2L , and D 3 receptors, even 30 min after D-264 application was terminated. Such persistent activation could be due to slow off-rate of D-264 from the receptor or, alternatively, D-264 could induce an active receptor conformation that returns to the original conformation state very slowly. It is also possible that D-264 could partition into the membrane compartment and become resistant to washout. Regardless of the mechanism underlying persistent signaling activation by D-264, this property of D-264 is observed with both D 2 and D 3 receptors and might contribute to its duration of action. Potent D-264-induced activation of MAPK and GIRK channels via D 2 /D 3 dopamine receptors could lead to increased cell survival. While the current experiments were performed in a heterologous expression system, the ability of D-264 to directly modulate two signaling pathways involved in cell proliferation leads us to suggest a hypothesis that direct modulation of D 3 receptor signaling might be partially responsible for the previously reported neuroprotective property of D-264.
Finally, we observed that the D 3 receptor-mediated cell proliferation exhibited a bell-shaped dose-response curve wherein no proliferation was observed at higher concentrations (>0.1-0.01 nM) of the agonists (Fig. 6b and c) . This was different from the results obtained with D 2L wherein, significant proliferation was observed at relatively higher concentrations (100 nM) of D-264 (Fig. 6a) . The most parsimonious explanation is that higher concentrations of agonists induce desensitization or tolerance at D 3 receptors but not at D 2 receptors; this would be consistent with our previous studies where we have reported and characterized the D 3 receptor tolerance properties (Kuzhikandathil et al. 2004 ). Alternatively, the higher concentrations of the agonists might induce specific D 3 receptor-linked negative feedback mechanisms that inhibits signaling pathways involved in cell proliferation.
Conclusion
In this report, we demonstrated that D-264 is a potent agonist at D 2S , D 2L , and D 3 dopamine receptors, leading to robust activation of MAPK and GIRK channels. (Li et al. 2010) .
